Cargando…

Glioblastoma, from disease understanding towards optimal cell-based in vitro models

BACKGROUND: Glioblastoma (GBM) patients are notoriously difficult to treat and ultimately all succumb to disease. This unfortunate scenario motivates research into better characterizing and understanding this disease, and into developing novel research tools by which potential novel therapeutics and...

Descripción completa

Detalles Bibliográficos
Autores principales: Boccellato, Chiara, Rehm, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424171/
https://www.ncbi.nlm.nih.gov/pubmed/35763242
http://dx.doi.org/10.1007/s13402-022-00684-7
_version_ 1784778182453362688
author Boccellato, Chiara
Rehm, Markus
author_facet Boccellato, Chiara
Rehm, Markus
author_sort Boccellato, Chiara
collection PubMed
description BACKGROUND: Glioblastoma (GBM) patients are notoriously difficult to treat and ultimately all succumb to disease. This unfortunate scenario motivates research into better characterizing and understanding this disease, and into developing novel research tools by which potential novel therapeutics and treatment options initially can be evaluated pre-clinically. Here, we provide a concise overview of glioblastoma epidemiology, disease classification, the challenges faced in the treatment of glioblastoma and current novel treatment strategies. From this, we lead into a description and assessment of advanced cell-based models that aim to narrow the gap between pre-clinical and clinical studies. Such in vitro models are required to deliver reliable and meaningful data for the development and pre-validation of novel therapeutics and treatments. CONCLUSIONS: The toolbox for GBM cell-based models has expanded substantially, with the possibility of 3D printing tumour tissues and thereby replicating in vivo tissue architectures now looming on the horizon. A comparison of experimental cell-based model systems and techniques highlights advantages and drawbacks of the various tools available, based on which cell-based models and experimental approaches best suited to address a diversity of research questions in the glioblastoma research field can be selected.
format Online
Article
Text
id pubmed-9424171
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-94241712022-08-31 Glioblastoma, from disease understanding towards optimal cell-based in vitro models Boccellato, Chiara Rehm, Markus Cell Oncol (Dordr) Review BACKGROUND: Glioblastoma (GBM) patients are notoriously difficult to treat and ultimately all succumb to disease. This unfortunate scenario motivates research into better characterizing and understanding this disease, and into developing novel research tools by which potential novel therapeutics and treatment options initially can be evaluated pre-clinically. Here, we provide a concise overview of glioblastoma epidemiology, disease classification, the challenges faced in the treatment of glioblastoma and current novel treatment strategies. From this, we lead into a description and assessment of advanced cell-based models that aim to narrow the gap between pre-clinical and clinical studies. Such in vitro models are required to deliver reliable and meaningful data for the development and pre-validation of novel therapeutics and treatments. CONCLUSIONS: The toolbox for GBM cell-based models has expanded substantially, with the possibility of 3D printing tumour tissues and thereby replicating in vivo tissue architectures now looming on the horizon. A comparison of experimental cell-based model systems and techniques highlights advantages and drawbacks of the various tools available, based on which cell-based models and experimental approaches best suited to address a diversity of research questions in the glioblastoma research field can be selected. Springer Netherlands 2022-06-28 2022 /pmc/articles/PMC9424171/ /pubmed/35763242 http://dx.doi.org/10.1007/s13402-022-00684-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Boccellato, Chiara
Rehm, Markus
Glioblastoma, from disease understanding towards optimal cell-based in vitro models
title Glioblastoma, from disease understanding towards optimal cell-based in vitro models
title_full Glioblastoma, from disease understanding towards optimal cell-based in vitro models
title_fullStr Glioblastoma, from disease understanding towards optimal cell-based in vitro models
title_full_unstemmed Glioblastoma, from disease understanding towards optimal cell-based in vitro models
title_short Glioblastoma, from disease understanding towards optimal cell-based in vitro models
title_sort glioblastoma, from disease understanding towards optimal cell-based in vitro models
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424171/
https://www.ncbi.nlm.nih.gov/pubmed/35763242
http://dx.doi.org/10.1007/s13402-022-00684-7
work_keys_str_mv AT boccellatochiara glioblastomafromdiseaseunderstandingtowardsoptimalcellbasedinvitromodels
AT rehmmarkus glioblastomafromdiseaseunderstandingtowardsoptimalcellbasedinvitromodels